As vehicles gain technological capabilities, car manufacturers are using an increasing number of computers and sensors to improve situational awareness and enhance the driving experience.
Like most scientists, Chengping Chai is not content with the surface of things: He wants to probe beyond to learn what’s really going on. But in his case, he is literally building a map of the world beneath, using seismic and acoustic data that reveal when and where the earth moves.
A partnership of ORNL, the Tennessee Department of Economic and Community Development, the Community Reuse Organization of East Tennessee and TVA that aims to attract nuclear energy-related firms to Oak Ridge has been recognized with a state and local economic development award from the Federal Laboratory Consortium.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
In the quest for advanced vehicles with higher energy efficiency and ultra-low emissions, ORNL researchers are accelerating a research engine that gives scientists and engineers an unprecedented view inside the atomic-level workings of combustion engines in real time.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
To better understand how the novel coronavirus behaves and how it can be stopped, scientists have completed a three-dimensional map that reveals the location of every atom in an enzyme molecule critical to SARS-CoV-2 reproduction.
A team of researchers has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease — the enzyme that enables the virus to reproduce.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.